Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application
Hepatocellular carcinoma (HCC) is on the rise worldwide, and its incidence in diabetic patients is two to three times that of non-diabetics. Current therapeutic options fail to provide considerable survival benefits to patients with HCC. There is a strong possibility that the FDA-approved antidiabet...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Elsevier
2022
|
| Subjects: | |
| Online Access: | https://doaj.org/article/243e31ff9d064d9ab4bb5a9d133137d8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|